MARCEL DE PAULA PEREIRA
Projetos de Pesquisa
Unidades Organizacionais
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
- Position Statement on the Use of Antiplatelet Agents and Anticoagulants in Patients Infected with the New Coronavirus (COVID-19)-2020(2020) SOEIRO, Alexandre de Matos; LEAL, Tatiana de Carvalho Andreucci Torres; PEREIRA, Marcel de Paula; LIMA, Eduardo Gomes; FIGUEIREDO, Ana Cristina Baptista da Silva; PETRIZ, Joao Luiz Fernandes; PRECOMA, Dalton Betolim; SERRANO JR., Carlos Vicente
- Viral infections and atherothrombosis: Another caution in the wake of COVID-19?(2020) PEREIRA, Marcel de Paula; LIMA, Eduardo Gomes; SERRANO JUNIOR, Carlos Vicente
- Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trial(2023) PEREIRA, M. D. P.; LIMA, E. G.; PITTA, F. G.; GOWDAK, L. H. W.; MIOTO, B. M.; CARVALHO, L. N. S.; DARRIEUX, F. C. D. C.; MEJIA, O. A. V.; JATENE, F. B.; SERRANO JR., C. VObjectives: Postoperative atrial fibrillation is the most common clinical complication after coronary artery bypass graft surgery. It is associated with a high risk of both stroke and death and increases the length of hospital stay and costs. This study aimed to evaluate anticoagulants in postoperative atrial fibrillation. Methods: A single-center, randomized, prospective, and open-label study. The trial was conducted in Heart Institute at University of São Paulo, Brazil. Patients who developed postoperative atrial fibrillation were randomized to anticoagulation with rivaroxaban or warfarin plus enoxaparin bridging. The primary objective was the cost-effectiveness evaluated by quality-adjusted life years, using the SF-6D questionnaire. The secondary end point was the combination of death, stroke, myocardial infarction, thromboembolic events, infections, bleeding, readmissions, and surgical reinterventions. The safety end point was any bleeding using the International Society on Thrombosis and Haemostasis score. Follow-up period was 30 days after hospital discharge. Results: We analyzed 324 patients and 53 patients were randomized. The median cost-effectiveness was $1423.20 in the warfarin group versus $586.80 in the rivaroxaban group (P = .002). The median cost was lower in the rivaroxaban group, $450.20 versus $947.30 (P < .001). The secondary outcome was similar in both groups, 44.4% in warfarin group versus 38.5% in the rivaroxaban group (P = .65). Bleeding occured in 25.9% in the warfarin group versus 11.5% in the rivaroxaban group (P = .18). Conclusions: Rivaroxaban was more cost-effective when compared with warfarin associated with enoxaparin bridging in postoperative atrial fibrillation after isolated coronary artery bypass grafting.
bookPart Imunossupressão e seguimento pós-transplante(2022) PEREIRA, Marcel de Paula; ÁVILA, Mônica SamuelbookPart Emergências cardiovasculares no transplantado cardíaco(2023) VIEIRA, Ivna Girard Cunha; NUNES, Jairo Tavares; PEREIRA, Marcel de Paula; AVILA, Mônica SamuelbookPart Acesso venoso central(2023) PEREIRA, Marcel de Paula; ANDRADE, Maria Carolina Diez de; MACHADO, Victor de Sá Guimarães Fleury; FRANCO, Rafael AlvesbookPart Edema agudo de pulmão(2023) OLIVEIRA, Lucas Lentini Herling de; CORREIA, Vinícius Machado; PEREIRA, Marcel de Paula; SOEIRO, Alexandre de MatosbookPart Miocardite(2023) ACCORSI, Rafael de Lima; FERNANDES, Fábio; PEREIRA, Marcel de Paula; MADRINI JUNIOR, VagnerbookPart Síndrome do desconforto respiratório agudo(2023) MACHADO, Victor Sá Guimarães Fleury; PEREIRA, Marcel de Paula; FRANCO, Rafael Alves